Annals of Clinical Microbiology, The official Journal of the Korean Society of Clinical Microbiology
| Primer type and target locus | Primer name | Nucleotide sequence (5′ → 3′) | Size, base pair |
|---|---|---|---|
| Rv0577 | Rv0577F | ATG CCC AAG AGA AGC GAA TAC AGG CAA | 786 |
| Rv0577R | CTA TTG CTG CGG TGC GGG CTT CAA | ||
| IS1561 (Rv3349c) | IS1561F | GCT GGG TGG GCC CTG GAA TAC GTG AAC TCT | 943 |
| IS1561R | AAC TGC TCA CCC TGG CCA CCA CCA TTG ACT | ||
| Rv1510 (RD4) | Rv1510F | GTG CGC TCC ACC CAA ATA GTT GC | 1,033 |
| Rv1510R | TGT CGA CCT GGG GCA CAA ATC AGT C | ||
| Rv1970 (RD7) | Rv1970F | GCG CAG CTG CCG GAT GTC AAC | 1,116 |
| Rv1970R | CGC CGG CAG CCT CAC GAA ATG | ||
| Rv3877/8 (RD1) | Rv3877/8F | CGA CGG GTC TGA CGG CCA AAC TCA TC | 999 |
| Rv3877/8R | CTT GCT CGG TGG CCG GTT TTT CAG C | ||
| Rv3120 (RD12) | Rv3120F | GTC GGC GAT AGA CCA TGA GTC CGT CTC CAT | 404 |
| Rv3120R | GCG AAA AGT GGG CGG ATG CCA GAA TAG T | ||
| Rv2073c (RD9) | Rv2073cF | TCG CCG CTG CCA GAT GAG TC | 600 |
| Rv2073cR | TTT GGG AGC CGC CGG TGG TGA TGA |
| Primer type and target locus | Primer name | Nucleotide sequence (5′ → 3′) | Size, base pair |
|---|---|---|---|
| Rv0577 | Rv0577F | ATG CCC AAG AGA AGC GAA TAC AGG CAA | 786 |
| Rv0577R | CTA TTG CTG CGG TGC GGG CTT CAA | ||
| IS1561 (Rv3349c) | IS1561F | GCT GGG TGG GCC CTG GAA TAC GTG AAC TCT | 943 |
| IS1561R | AAC TGC TCA CCC TGG CCA CCA CCA TTG ACT | ||
| Rv1510 (RD4) | Rv1510F | GTG CGC TCC ACC CAA ATA GTT GC | 1,033 |
| Rv1510R | TGT CGA CCT GGG GCA CAA ATC AGT C | ||
| Rv1970 (RD7) | Rv1970F | GCG CAG CTG CCG GAT GTC AAC | 1,116 |
| Rv1970R | CGC CGG CAG CCT CAC GAA ATG | ||
| Rv3877/8 (RD1) | Rv3877/8F | CGA CGG GTC TGA CGG CCA AAC TCA TC | 999 |
| Rv3877/8R | CTT GCT CGG TGG CCG GTT TTT CAG C | ||
| Rv3120 (RD12) | Rv3120F | GTC GGC GAT AGA CCA TGA GTC CGT CTC CAT | 404 |
| Rv3120R | GCG AAA AGT GGG CGG ATG CCA GAA TAG T | ||
| Rv2073c (RD9) | Rv2073cF | TCG CCG CTG CCA GAT GAG TC | 600 |
| Rv2073cR | TTT GGG AGC CGC CGG TGG TGA TGA |
| No | Culture | NGS (> 10 % relative abundance) | Read count | Infection | Antibiotics* | Catheter removal | Clear up on day 10 | Relapse within 2 months |
|---|---|---|---|---|---|---|---|---|
| CAPD01 | Staphylococcus epidermidis | Staphylococcus spp. (20.4 %) | 14,841 | yes | cefazolin, tobramycin, vancomycin | yes | yes | no |
| CAPD02 | Escherichia coli | Escherichia spp. (99.8 %) | 96,528 | yes | rifaximin, meropenem | no | yes | yes |
| CAPD03 | No growth | Lactobacillus spp. (82.1 %) | 86,053 | no | piperacillin-tazobactam | – | – | – |
| CAPD04 | Serratia marcescens | Serratia spp. (74.6 %) | 59,609 | yes | vancomycin, ceftazidime | no | no | yes |
| CAPD05 | Micrococcus spp. | Kytococcus spp. (25.2 %) Lactobacillus spp. (19.2 %) | 13,260 | yes | cefazolin, ceftazidime | no | yes | no |
| CAPD06 | No growth | Enterobacteriaceae (11.9 %) Lactobacillus spp. (11.0 %) | 83,717 | yes | meropenem, rifaximin | no | no | no |
| Combination of antibiotics | Interaction | MDR | XDR | Total |
|---|---|---|---|---|
| No. (%) | No. (%) | No. (%) | ||
| Colistin+Linalool | Synergy (criteria 1) | 10 (100) | 39 (95.1) | 49 (96.0) |
| Synergy (criteria 2) | 9 (90.0) | 38 (92.6) | 47 (92.1) | |
| Indifference | 1 (10.0) | 3 (7.3) | 4 (7.8) | |
| Antagonism | 0 (0) | 0 (0) | 0 (0) | |
| Bactericidal | 8 (80.0) | 30 (73.1) | 38 (74.5) |